Featured Story

Bayer signs cardiovascular genomics alliance with Harvard, MIT

Germany's Bayer already partners with MIT and Harvard on oncology research, and now the partnership is being upgraded to include cardiovascular genomics and drug discovery. The expansion of the alliance into cardiovascular genomics will be about the search for genetic biomarkers of patient risk or suitability to particular drugs that treat cardiovascular conditions like heart disease.

Cancer Dx startup Helomics joins U.K. genomics initiative alongside big biopharmas

Helomics is lending its tumor profiling technology and diagnostic expertise to a U.K. genomics initiative, teaming up with Big Pharma and researchers to uncover new biomarkers and develop advanced tests.

Myriad extends companion Dx deal with AstraZeneca to pancreatic cancer

Myriad Genetics is expanding its companion diagnostics partnership with AstraZeneca, planning to use Myriad's BRACAnalysis test to see which metastatic pancreatic cancer patients respond to AstraZeneca's Lynparza (olaparib). 

White House calls for advancing rapid diagnostics to combat drug-resistant bacteria

The diagnostics industry will play a significant role in the Obama administration's just-released national action plan to combat the rise of antibiotic-resistant bacteria, such as CRE, which was implicated in the recent death of at least two patients in Los Angeles and many illnesses nationwide.

GE Healthcare's pathology arm to use Omnyx's software for digital analysis of specimens

GE Healthcare announced that its diagnostic laboratory company, Clarient, will soon deploy Omnyx's proprietary software, as pathology pivots away from visual diagnosis and toward quantitative computer-based tools.